Nebenwirkungen · Ajovy
AJOVY 225 mg solution for injection in pre-filled syringe AJOVY 225 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 5
HOS-142239 · Präparat HOS-098784
Immunogenicity In placebo-controlled studies, 0.4 % of patients (6 out of 1,701) treated with fremanezumab developed anti-drug antibodies (ADA). The antibody responses were of low titer. One of these 6 patients developed neutralising antibodies. With 12 months of treatment, ADA were detected in 2.3% of the patients (43 out of 1,888) with 0.95% of the patients developing neutralising antibodies. The safety and efficacy of fremanezumab were not affected by ADA development.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-04T11:30:00Z · SHA-256 1d65a40c3b8eb6e115cc741e0387b78196f4c978fd87567266b9a3547277e3e3 · Passage b4aab42f4271a821a619c41aa6b48d3486a901763b497bc984d358e78604bd11 · Zeichen 2790–3265 im Abschnitt